Actively Recruiting
Interaction of Volatile Anesthetics With Magnesium
Led by Christoph Czarnetzki · Updated on 2024-05-10
96
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
Sponsors
C
Christoph Czarnetzki
Lead Sponsor
C
Centre Hospitalier du Centre du Valais
Collaborating Sponsor
AI-Summary
What this Trial Is About
Magnesium and volatiles anesthetics both have an effect on the neuromuscular transmission. The primary objective of the study is to quantify the effect of a perfusion of intravenous magnesium on neuromuscular transmission measured by electromyography device TetraGraph device in patients undergoing general anesthesia with volatile anesthetics (desflurane, sevoflurane and isoflurane) as compared to intravenous anesthesia with propofol.
CONDITIONS
Official Title
Interaction of Volatile Anesthetics With Magnesium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients, age 18 to 65 years inclusive
- American Society of Anesthesiology [ASA] status I or II
- Body mass index 19 - 30 kg/m2
- Patient scheduled for elective surgery lasting ≥ 60 minutes
- Patient is able to read and understand the information sheet and to sign and date the consent form.
- Negative urinary or serum pregnancy test (not applicable if status post hysterectomy or tubal ligation or menopausal woman)
You will not qualify if you...
- Surgery with need for neuromuscular block
- Contraindication for general anesthesia with laryngeal mask airway, such as gastro-oesophageal reflux.
- Hypersensitivity or allergy to magnesium sulfate or propofol
- Contraindication to volatile anesthetics such as malignant hyperthermia
- Patients with neuromuscular disease
- Patients receiving medications known to influence neuromuscular function (for instance, aminoglycosides or phenytoine)
- Known electrolyte abnormalities (for instance, hypermagnesemia)
- Atrioventricular heart block
- Patients with magnesium treatment within 48 hours before start of study
- Liver insufficiency (bilirubine <1.5x, ALAT/ASAT<2.5x the upper limit of normal value)
- Renal insuffisancy (créatinine <1.5x upper limit of normal value, clearance<30ml/minute)
- Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial.
- Pregnant or breast-feeding women.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Anesthesiology and Intensive Care, Valais Hospital
Sion, Switzerland, 1951
Actively Recruiting
Research Team
C
Christoph Czarnetzki, MD, MBA
CONTACT
S
Sina Grape, MD, MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here